Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.

Area of Science:

• Hematology
• Oncology
• Cardiology

Background:

• Light chain amyloidosis (AL) therapy is evolving, with a new standard of care emerging.
• Early death, primarily due to cardiac complications, remains a critical challenge in AL management.
• AL treatment strategies differ from multiple myeloma due to unique patient factors and disease biology.

Purpose of the Study:

• To review recent advances in plasma cell-directed therapies for AL.
• To highlight unique aspects of AL biology and treatment development compared to multiple myeloma.
• To explore novel therapeutic targets and strategies, including anti-fibrillar therapies, for AL.

Main Methods:

• Review of recent clinical studies and ongoing trials in AL therapy.
• Analysis of data from the ANDROMEDA study (NCT03201965) on anti-CD38 antibody combinations.
• Exploration of emerging therapies targeting BCMA, BCL-2 family, and anti-amyloid fibrils.

Main Results:

• Addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone improved response rates in AL.
• Improved depth and kinetics of hematologic response and organ response were observed with daratumumab combination.
• Despite improved responses, overall death rates remained similar between treatment arms in the ANDROMEDA study.

Conclusions:

• While novel therapies enhance response rates in AL, reducing early mortality, particularly cardiac death, requires further investigation.
• Ongoing research into targeted therapies (BCMA, BCL-2 inhibitors) and novel agents holds promise for AL treatment.
• Future clinical development will focus on anti-fibrillar therapies to improve survival in advanced cardiac AL patients.